Solasia Pharma K.K
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial d… Read more
Solasia Pharma K.K (9SO) - Net Assets
Latest net assets as of June 2025: €1.28 Billion EUR
Based on the latest financial reports, Solasia Pharma K.K (9SO) has net assets worth €1.28 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.86 Billion) and total liabilities (€588.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.28 Billion |
| % of Total Assets | 68.45% |
| Annual Growth Rate | -12.72% |
| 5-Year Change | -68.35% |
| 10-Year Change | N/A |
| Growth Volatility | 38.52 |
Solasia Pharma K.K - Net Assets Trend (2016–2024)
This chart illustrates how Solasia Pharma K.K's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Solasia Pharma K.K (2016–2024)
The table below shows the annual net assets of Solasia Pharma K.K from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.16 Billion | -38.35% |
| 2023-12-31 | €1.88 Billion | -29.56% |
| 2022-12-31 | €2.66 Billion | +2.90% |
| 2021-12-31 | €2.59 Billion | -29.16% |
| 2020-12-31 | €3.65 Billion | -47.20% |
| 2019-12-31 | €6.92 Billion | -2.40% |
| 2018-12-31 | €7.09 Billion | +14.15% |
| 2017-12-31 | €6.21 Billion | +80.82% |
| 2016-12-31 | €3.43 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solasia Pharma K.K's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 126900000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €4.43 Billion | 383.23% |
| Total Equity | €1.16 Billion | 100.00% |
Solasia Pharma K.K Competitors by Market Cap
The table below lists competitors of Solasia Pharma K.K ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ANGLE plc
OTCQX:ANPCF
|
$34.42 Million |
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
$34.43 Million |
|
Lotus Bakeries NV
PINK:LOTBY
|
$34.44 Million |
|
Cardlytics Inc
NASDAQ:CDLX
|
$34.46 Million |
|
Mithril Silver and Gold Ltd
AU:MTH
|
$34.42 Million |
|
Kpx Green Chem
KO:083420
|
$34.41 Million |
|
Fosterville South Exploration Ltd
OTCQX:FSXLF
|
$34.41 Million |
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
$34.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solasia Pharma K.K's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,874,000,000 to 1,157,000,000, a change of -717,000,000 (-38.3%).
- Net loss of 1,941,000,000 reduced equity.
- New share issuances of 1,215,000,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.94 Billion | -167.76% |
| Share Issuances | €1.22 Billion | +105.01% |
| Other Changes | €9.00 Million | +0.78% |
| Total Change | €- | -38.26% |
Book Value vs Market Value Analysis
This analysis compares Solasia Pharma K.K's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €70.75 | €0.15 | x |
| 2018-12-31 | €67.71 | €0.15 | x |
| 2019-12-31 | €59.42 | €0.15 | x |
| 2020-12-31 | €29.77 | €0.15 | x |
| 2021-12-31 | €19.38 | €0.15 | x |
| 2022-12-31 | €15.85 | €0.15 | x |
| 2023-12-31 | €10.77 | €0.15 | x |
| 2024-12-31 | €5.31 | €0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solasia Pharma K.K utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -167.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -614.24%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.18x
- Recent ROE (-167.76%) is below the historical average (-69.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -13.82% | -94.64% | 0.14x | 1.08x | €-817.78 Million |
| 2017 | -16.23% | -245.22% | 0.06x | 1.07x | €-1.63 Billion |
| 2018 | -34.17% | -761.64% | 0.04x | 1.09x | €-3.13 Billion |
| 2019 | -27.00% | -142.52% | 0.16x | 1.15x | €-2.56 Billion |
| 2020 | -113.04% | -909.03% | 0.08x | 1.58x | €-4.49 Billion |
| 2021 | -95.79% | -443.29% | 0.18x | 1.22x | €-2.74 Billion |
| 2022 | -95.72% | -233.33% | 0.35x | 1.18x | €-2.81 Billion |
| 2023 | -59.34% | -180.23% | 0.28x | 1.19x | €-1.30 Billion |
| 2024 | -167.76% | -614.24% | 0.23x | 1.18x | €-2.06 Billion |
Industry Comparison
This section compares Solasia Pharma K.K's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $10,143,087,808
- Average return on equity (ROE) among peers: -84.15%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solasia Pharma K.K (9SO) | €1.28 Billion | -13.82% | 0.46x | $34.42 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |